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Abstract
Hyperkalemia is a metabolic problem that may be life threatening if left untreated. Cardiac arrhythmias may develop
with the potential to lead to cardiac arrest and death. Hyperkalemia can oftentimes be undiagnosed due to the lack of
clear, specific symptoms and inconclusive variations in electrocardiogram (ECG) readings and lab values. Therefore, it is
important to recognize risk factors that can potentially increase serum potassium levels. Screening for medications
that increase serum potassium levels and educating patients
are steps that both inpatient and outpatient health care
professionals can take to increase early detection and prevention of a hyperkalemic episode. It is also important for
health care professionals to understand the various treatment options if hyperkalemia does occur. Treatment varies
between inpatient and outpatient settings. Inpatient treatments often include cation exchange resins, loop diuretics,
insulin, sodium bicarbonate, beta-agonists and calcium infusions; whereas, long-term outpatient management has been
limited to chronic dialysis. Newer agents, sodium zirconium
and patiromer, may offer significant benefits for the outpatient management of chronic hyperkalemia.
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Introduction
As a critical intracellular cation in the body, potassium plays
a large role in cellular function. Changes in serum potassium
levels affect the resting membrane potential of cells which
can lead to dysfunction in muscles, nerves and heart.1 There
are two main ways the body regulates potassium levels.2
First, potassium may stimulate the pancreas to release
insulin. Increased insulin levels cause the transportation of
potassium from the extracellular space into cells through
the sodium-potassium adenosine triphosphatase (Na+/K+
ATPase) pump. Secondly, increased levels of serum potassium stimulate the activation of the renin angiotensin system
(RAS) leading to the secretion of aldosterone. Aldosterone
causes the kidney to retain sodium and excrete potassium to
maintain adequate serum potassium levels. See Figure 1.3

Figure 1. Regulation of Potassium Excretion in the Kidney via the Renin-Angiotensin-Aldosterone System.3
Impaired release due to NSAIDs,
beta-blockers, cyclosporine, tacrolimus, diabetes or advanced age
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Renin release from the glomerular capsule stimulates angiotensin I which in turn stimulates angiotensin II, then aldosterone, which is responsible for sodium reabsorption and potassium secretion from the principal cell in the collecting duct, thereby causing potassium excretion in the collecting duct urine. Factors affecting this process are noted in the figure.
Abbreviations: NSAIDs-nonsteroidal anti-inflammatory drugs; ACE–angiotensin converting enzyme; ARBs–angiotensin receptor blocking
agents.
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Hyperkalemia occurs when potassium homeostasis is disturbed. Nearly 80 percent of cases are a result of the body
not being able to excrete proper amounts of potassium. 4 Additionally, supplemental potassium from diet or salt substitutes, as well as the use of drugs that impair the excretion of
potassium (most commonly potassium sparing diuretics and
aldosterone antagonists), can increase potassium levels. Normal serum potassium levels range from 3.5 to 5.0 mEq/L.
Hyperkalemia is specifically defined as a serum potassium
concentration exceeding 5.0 mEq/L. An emergent hyperkalemic episode may be seen with serum potassium levels
above 6.5 mEq/L, although the association of degree of severity of hyperkalemia and life threatening arrhythmias is
still unclear.5-7 Mortality related to hyperkalemia has been
studied although it is unclear if hyperkalemia is simply a
marker for severity of illness or is a cause of mortality in itself. A large retrospective study of 245,808 veterans was reviewed for an association between chronic kidney disease,
treatment with an ACE inhibitor (angiotensin-converting
enzyme inhibitor) or ARB (angiotensin II-receptor blocker),
hyperkalemia and death.8 Results from this study did demonstrate a clear increased risk associated with increasing potassium levels. Interestingly, the patients with chronic kidney
disease had a lower risk of death than patients with no kidney disease with comparable potassium levels, suggesting a
tolerance to higher levels which occur over a more prolonged
period. It is important to recognize the impact of hyperkalemia in the outpatient and inpatient settings and develop
strategies for health care professionals to aid in prevention
and treatment.
Clinical Considerations
Patient Presentation
Hyperkalemia is often difficult to diagnose due to vague
symptomatic complaints and no specific signs directly associated with the condition.9 Patients may describe generalized
weakness, nausea, vomiting, diarrhea, paresthesias or palpitations; however patients are often asymptomatic, extending
the time it takes to seek treatment.6 Presentation depends on
the patient’s underlying condition which predisposed the
individual to the development of hyperkalemia.4 These may
include disorders which impair renal excretion of potassium
such as mineralocorticoid deficiency and renal insufficiency
or failure.2 Acidosis, tissue damage from rhabdomyolysis,
burns, trauma, hyperosmolar states including uncontrolled
diabetes, insulin deficiency or resistance, and tumor lysis
syndrome can cause a shift of potassium into the extracellular space.
Cardiac and neurologic symptoms tend to predominate when
examining symptomatic patients.9 Cardiac examination of a
hyperkalemic patient may uncover extrasystoles, pauses or
bradycardia. Diminished deep tendon reflexes and/or decreased motor strength may be revealed upon neurologic
examination. Rarely, patients will present with muscle paralysis and hypoventilation. Renal failure associated with hyperkalemia may present with edema and/or skin changes.
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Electrocardiogram (ECG) Changes
Electrocardiogram (ECG) findings may reveal the first manifestations of hyperkalemia in a patient, therefore playing a
large role in diagnosis.2,10 Hyperkalemic patients should be
on continuous cardiac monitoring to evaluate for any changes in cardiac rhythm. The ECG may be an insensitive
indicator of severity of hyperkalemia, but needs to still be
monitored for patient safety.6 Some authors correlate ECG
changes with specific serum potassium levels.2,6,10-14 However, this is not consistently supported.13-15 Interpatient variability is high, and life-threatening arrhythmias can occur at
any level of hyperkalemia. The earliest ECG signs associated
with hyperkalemia include narrowing/peaking of the
T waves caused by an increase in rate of ventricular repolarization, shortened QT interval and ST-segment depression.
2,6,10-14,16 Widening of the PR interval then occurs followed by
a delay through the His-Purkinje system, loss of the P wave,
delay through the atrial myocardium, widening of the QRS
complex and then a delay through the ventricular myocardium. If hyperkalemia is not corrected, the QRS complex will
merge with the T wave resulting in a sinusoidal wave
appearance. This is followed by ventricular fibrillation or
asystole.
Lab Values
Accuracy of the laboratory report of hyperkalemia should
always be ascertained as there are several factors which may
contribute to falsely elevated serum potassium measurement. 2,5,7,9 Mechanical or procedural issues which may falsely elevate potassium include trauma during venipuncture,
clenching a fist during phlebotomy and drawing blood samples from a vein or line into which potassium is being infused. Other causes include hemolysis, leukocytosis, thrombocytosis and genetic syndromes such as familial pseudohyperkalemia or hereditary spherocytosis.
The relationship between potassium levels and the symptomatology of the patient is not always consistent.17 For example, patients with chronically elevated potassium will present
asymptomatically at much higher levels than other patients.
Blood urea nitrogen (BUN) and creatinine levels should be
drawn to evaluate the patient’s renal status in renal insufficiency. Serum calcium levels may be evaluated as a differential diagnosis. Hypocalcemia can exacerbate cardiac rhythm
abnormalities resulting in hyperkalemia-like ECG readings or
exacerbate hyperkalemia irregularities. Urinalysis should be
performed to evaluate for evidence of glomerulonephritis
which could lead to elevated serum potassium levels. Glucose
levels in diabetic patients should be monitored to rule out
uncontrolled diabetes and insulin deficiency or resistance as
a cause of hyperkalemia. Cortisol and aldosterone levels
should be evaluated when other causes are eliminated to
assess for mineralocorticoid deficiency. Arterial or venous
blood gases should be evaluated if acidosis is suspected.2
Acute Management of Hyperkalemia
Treatment of hyperkalemia involves three specific goals: stabilization of the myocardium, promotion of an intracellular
shift of potassium and elimination of excess extracellular
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potassium. Some or all of these methods may be employed
depending on the severity, underlying cause and general condition of the patient.5,6,9,12
For the treatment of hyperkalemia, the American Heart Association Advanced Cardiovascular Life Support (ACLS) algorithms divide hyperkalemia protocols into three divisions:
mild, moderate and severe management.18 Table 1 contains
the ranges of potassium and ECG abnormalities generally
related to hyperkalemia.10,13,14
Because hyperkalemia can cause lethal cardiac arrhythmias,
prompt recognition, diagnosis and treatment are essential to
optimize patient outcomes.6,18 The treatment of hyperkalemia is contingent on patient acuity and clinical presentation.
The creation, implementation and practice of proper protocols are essential to patient care.19 Pharmacists in an inpatient setting can help identify patients at an elevated risk for
developing hyperkalemia.20 Evaluation of patients’ underlying conditions and current medications can help to expedite
the diagnosis process.
Treatment of Mild Hyperkalemia
Cation Exchange Resins
Two forms of cation exchange resins are standard for the
treatment of hyperkalemia: sodium polystyrene (SPS) and
calcium resonium, although only SPS is available in the United States.6 Sodium polystyrene acts by partially releasing
sodium ions which are replaced by potassium ions in the
large intestine.5,21 Additionally, SPS exchanges the sodium for
calcium, ammonium and magnesium. In comparison, calci-

um resonium exchanges calcium for potassium ions in the
large intestine.21 Each agent can be given orally or rectally.
Exchange resins are commonly dosed between 15 to 30
grams (g) in 50 to 100 milliliters (mL) of 20 percent sorbitol.
The onset of action is two hours with a peak effect at four to
six hours. Exchange resins should not be used exclusively to
treat acute hyperkalemia due to their slow onset of action.
The health care provider should note the potential of intestinal necrosis and bowel perforation as these are the major
adverse effects seen with these resins.10 Several authors suggest the efficacy of these exchange resins are not supported
by evidence and, given the potential for harm, may not be
suitable for management of hyperkalemia.5,22-23
Loop Diuretics
When the patient’s urine output is 30 mL/hour or more, renal excretion is an effective route to eliminate potassium.6
Notably, 40 to 80 mEq of potassium is excreted in the urine
daily representing 90 percent of absorbed potassium. Loop
diuretics, such as furosemide (Lasix), are the preferred
agents. The American Heart Association, in their ACLS guidelines, recommends dosing furosemide between 40 to 80 mg
intravenously (IV).18 The onset of action of IV furosemide
usually occurs in five minutes, and peak action occurs about
30 minutes after administration. Side effects may include
dehydration and electrolyte disturbances such as hypokalemia and metabolic acidosis.24 Furosemide can be used alone
or in adjunct with cation exchange resins for patients with a
moderate elevation in potassium level and no ECG abnormalities.12

Table 1. Serum Potassium Levels and Associated ECG Changes.10,13,14
Serum Potassium
Range
Mild hyperkalemia
(5.5-6.5 mEq/L)
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Possible ECG Abnormalities
Peaked T waves

Moderate hyperkalemia
(6.6-8.0 mEq/L)

Peaked T waves
Prolonged PR segment
Decreased amplitude of P wave
Prolonged QRS complex
ST-segment elevation
Ectopic beats and escape rhythms

Severe hyperkalemia
(>8.0 mEq/L)

Loss of P wave
Prolonged widening of QRS complex
Sine wave
Axis deviations
Bundle branch blocks
Fascicular blocks
Ventricular fibrillation
Asystole
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Treatment of Moderate Hyperkalemia
Insulin
Insulin therapy has been the most consistent method of shifting potassium into cells.5,10 While insulin is a well-established
therapy in an emergent hyperkalemic setting, there is limited
data to support the difference between varying regimens of
insulin to acutely lower a serum potassium concentration.
Harel and Kamel reported that one-fifth of an insulin treated
cohort experienced hypoglycemia, and, thus, supplemental
glucose should be administered with insulin.25 The use of 10
units IV bolus of regular insulin with 25 grams of glucose (50
mL of 50 percent dextrose in water) is most commonly recommended in patients with blood glucose less than 250 mg/
dl.5 For patients with blood glucose above this level, only the
insulin is indicated. With insulin intervention, serum potassium levels decrease within 15 minutes with a peak effect of
approximately 60 minutes and a duration of four to six
hours.10 Nurses and other attentive health care providers
should monitor for signs and symptoms of hypoglycemia:
diaphoresis, chills, clamminess, irritability, confusion, dizziness and nausea. Blood glucose levels should be evaluated
every hour if the patient is on an insulin drip.25
Bicarbonate
Sodium bicarbonate is an alkalinizing agent that promotes
potassium excretion and was considered first-line therapy
for hyperkalemia for many years.26,27 The effectiveness of
bicarbonate therapy is unclear as studies show limited results.22,28,29 Sodium bicarbonate has been reported to be effective in patients with concurrent metabolic acidosis. 5,10
Bicarbonate therapy can be given either as a continuous infusion or a bolus dose of 50 mEq over five minutes.10 An excess
of bicarbonate therapy may cause alkalosis, volume overload
and hypernatremia.
Beta-agonists
Beta-agonists are believed to work through the Na+-K+
ATPase pump to shift potassium intracellularly. 30 The effect
of nonselective beta-agonists on serum potassium is inconsistent, and treatment of hyperkalemia is an unlabeled use of
albuterol.2,29,30 Sood and colleagues reported that one-third
of patients showed no response to beta-agonists.10 Patients
who may be taking beta-blocking agents may not be responsive to beta-agonists.6 This is of particular concern since
many of the patients at risk for hyperkalemia are also candidates for beta-blocker therapy. A systematic review and
meta-analysis conducted by Mahoney et al. determined the
combination of nebulized beta-agonists with insulin and glucose provided a greater effect on serum potassium than either regimen alone.22 Beta-agonists can be delivered through
three different routes: IV, nebulizer or metered-dose inhaler.5 Albuterol, delivered via nebulizer, is prescribed between
10 to 20 mg in 4 mL of normal saline or via 0.5 mg IV infusion. Serum potassium levels decrease within 30 minutes
with some effect seen in one to two minutes. The peak effect
occurs at 40 to 80 minutes after administration and has a
duration of effect for four to six hours.31 Doses of albuterol
used for hyperkalemia are higher than those used for asthma, so caution is advised if using this therapy in patients
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with a medical history of arrhythmias or coronary artery
disease.5,10,31 With beta-agonist administration, the patient
should be monitored for major adverse effects such as tremor, tachycardia, anxiety and flushing.
Treatment of Severe Hyperkalemia
In addition to the therapies utilized to treat mild and moderate hyperkalemia, calcium infusions may also be considered
in a patient with severe hyperkalemia. Hemodialysis is typically a last-line treatment option for these patients.
Calcium
Calcium agents are first-line treatment for patients with
severe hyperkalemia.6,10,32 Calcium raises the threshold potential and stabilizes cardiac myocyte membranes against
inappropriate depolarization, thus lowering the risk of arrhythmias. Calcium infusions do not directly affect serum
potassium level; thus, administration of calcium should be
paired with another therapy to decrease serum potassium
levels. Because of the irregular nature of cardiac arrhythmias,
calcium infusions are recommended if any ECG changes indicate hyperkalemia. Prophylactic administration of calcium
should be administered to any patient who is at a high risk
for developing arrhythmias.
Calcium gluconate and calcium chloride are two forms of
calcium that are commonly employed in severe hyperkalemia. 5,10 Although no strong evidence exists for the selection
and proper administration of either salt,33 calcium gluconate
is used more frequently and is given as a bolus of 500 to
1000 mg (5 to 10 mL of a 10 percent solution) IV over two to
five minutes.5,32 The onset of action occurs within three to
five minutes, and the duration is approximately 30 minutes
to one hour.10,34 This dose is repeated if needed to control the
ECG until normalization of the serum potassium is achieved
with other methods. Calcium chloride may be the preferred
agent in patients in cardiac arrest, with shock or with impaired hepatic perfusion since the gluconate form requires
metabolism in the liver to be active.
Calcium chloride provides three times the calcium ion per
gram of salt as compared to calcium gluconate; therefore,
some prescribers prefer the chloride salt, particularly in
more emergent cases.18 Calcium chloride is given in the same
dose as the gluconate, 500 mg to 1000 mg IV over two to five
minutes. The chloride salt is more caustic, and risk of venous
irritation or tissue injury with extravasation limits its use as
first-line. Hourly assessments of the IV site should be completed if the patient receives calcium chloride to identify any
potential venous or tissue harm.10
Calcium administration is a concern in patients with coexisting digitalis toxicity, since hypercalcemia can potentiate the
bradyarrhythmias and possibly induce cardiac arrest.10 It
has been recommended that calcium should only be used in
patients taking digitalis if there is loss of P waves or a widened QRS complex.35 If calcium is used in patients also receiving any digitalis product, the calcium should be diluted in
250 ml of 5 percent dextrose and administered more slowly
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as a 30 minute infusion to minimize the sudden influx of calcium into the myocytes.
Despite the lack of clinical trials demonstrating the benefits
of calcium in hyperkalemia, calcium has been part of the
management strategy for over 100 years.10 It is proposed
that a randomized controlled trial be conducted to look at
meaningful outcomes with the use of bolus doses versus continuous infusion of calcium in patients at risk for arrhythmias
associated with hyperkalemia.33
Dialysis
Hemodialysis should be reserved when other measures to
reduce serum potassium levels are exhausted or ineffective.10 In patients with life-threatening hyperkalemia, hemodialysis can rapidly eliminate large amounts of potassium.
This was demonstrated in a study by Blumberg et al. in which
plasma potassium was measured in 10 patients with terminal renal failure undergoing maintenance hemodialysis. 36
Potassium levels decreased from 5.63 to 4.29 mmol/liter
during the one hour dialysis as compared to a drop from 5.62
to 4.7 after insulin-glucose infusion. The results of this study
were consistent with those of Zehnder et al.37 in that the use
of low-potassium and glucose-free dialysate enhanced potassium removal. Additionally, Gutzwiller et al. demonstrated
acceleration of the blood pump speed increased the rate of
potassium removal.38
Roseman et al. proposed the use of peritoneal dialysis (PD) in
patients presenting with severe hyperkalemia who are established PD patients.39 The authors present such a case and the
successful use of manual exchanges to decrease potassium in
addition to the standard treatments. Although the authors
acknowledge the more rapid removal of potassium by
hemodialysis, they cite a number of reasons PD may be a reasonable consideration. Hemodialysis requires insertion of a
central venous catheter which involves time and risk, and
there may be delays in initiating therapy because of needing
support staff and equipment. The PD patient can be treated
with minimal delay using their existing catheter if the emergency department is prepared with PD supplies and appropriately trained personnel.
Outpatient Strategies/Monitoring
Although the exact prevalence of hyperkalemia in the outpatient community based practice is unknown, patients with
asymptomatic and mild hyperkalemia may be encountered in
the community or ambulatory setting. The ability to recognize elevated potassium levels and manage chronic
hyperkalemia can help prevent hyperkalemic emergencies.
Pharmacists can assist in the management of chronic hyperkalemia in patients who have elevated serum potassium levels but do not need immediate potassium reduction. These
levels are commonly seen in patients with chronic kidney
disease (CKD) or patients on RAS inhibitors in conjunction
with other potassium altering conditions or medications.
Pharmacists are able to counsel patients on the importance
of diet in regulating potassium levels as well as monitor drug
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agents that may contribute to hyperkalemia. Within the outpatient setting, there are various agents including herbal and
nutritional supplements which may cause or contribute to
hyperkalemia (Table 2). A pharmacist must recognize these
agents and be able to counsel patients in order to lower the
risk of developing hyperkalemia.
Pharmacists should counsel patients on restricting dietary
potassium to 2 to 3 g/day.4 Foods high in potassium include
bananas, melons and orange juice.2 Patients, especially those
who are renally impaired, should discontinue supplemental
potassium and salt substitutes.2,4 Ultimately, any drugs that
interfere with potassium homeostasis should be discontinued if the risks outweigh benefits. Potassium excretion can
be encouraged by providing recommendations to the physician to prescribe loop diuretics, thiazide diuretics or fludrocortisone if hypoaldosteronism is present.
Specific ambulatory care sites, such as rural dialysis centers,
provide care to patients with CKD who have a 50 percent
risk of developing hyperkalemia.1 Other ambulatory care
sites have large portions of patients with other chronic medical conditions such as heart failure, diabetes or other renal
conditions. In these patients, the addition of a RAS inhibitor
or aldosterone antagonist further increases the risk for developing hyperkalemia. Although a patient may not be experiencing a hyperkalemic emergency, there are still instances
when a patient may need a prompt (six to 12 hour) reduction in serum potassium in an outpatient or ambulatory care
setting. This scenario is most commonly seen in patients
with CKD, and dialysis is the first-line treatment. Although
mainly an inpatient treatment, gastrointestinal cation exchangers can be used at inpatient doses until dialysis is possible. Serum potassium levels should be evaluated no sooner
than two hours after dialysis due to rebound increases in
serum potassium immediately seen following treatment.40
Patients on dialysis who drink water with high fluoride levels can also have fluoride toxicity. This will decrease aldosterone synthesis that can also contribute to hyperkalemia.2
Newer Therapies
Methods available for the long-term management of chronic
hyperkalemia in the outpatient setting have been limited;
however, two newer agents have been studied to enhance
potassium elimination: patiromer and sodium zirconium.
Patiromer was approved by the U.S. Food and Drug Administration in October 2015 for the treatment of hyperkalemia
and is marketed under the brand name Veltassa®.41
Patiromer is intended as a treatment for mild to moderate
hyperkalemia primarily associated with chronic kidney disease.42 Patiromer is a nonabsorbable polymer which acts in
the distal colon to increase the fecal excretion of potassium
by binding potassium in exchange for calcium. Dosing is initiated at 8.4 grams once daily and adjusted weekly in increments of 8.4 grams based on serum potassium levels up to a
maximum of 25.2 grams. Doses should be administered at
least three hours before or three hours after other oral
medications to avoid absorption problems with the other
medications. The product is available as a powder for oral
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Table 2. Drugs Commonly Associated with Hyperkalemia.2
Drug Class

Mechanism Contributing to Hyperkalemia

Angiotensin II receptor blockers (ARBs)
Angiotensin converting enzyme inhibitors (ACEIs)

Decreased aldosterone synthesis

Azole Antifungals

Decreased aldosterone synthesis

Beta-Blockers

Decreased sodium-potassium adenosine triphosphate pump
(Na+/K+ ATPase) activity

Digoxin (cardiac glycoside)

Decreased Na+/K+ ATPase activity at toxic levels

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Decreased prostaglandin production resulting in suppressed
renin and aldosterone secretion

Amiloride and Triamterene

Increased potassium retention by reducing the electrical gradient between the intracellular space and the renal tubule

Spironolactone

Inhibited binding of aldosterone to receptors in the renal
tubule

Herbal Remedies (milkweed, lilly of the valley, Siberian
ginseng, Hawthorn berries or preparations from dried
toad skin also known as Bufo, Chan’su or Senso)

Decreased Na+/K+ ATPase activity

Supplements (Noni juice, alfalfa, dandelion, horsetail
and nettle)

Contain high potassium levels

suspension and needs to be prepared in water just prior to
administration. Patiromer is not recommended in patients
with severe constipation, bowel obstruction or impaction, or
any other abnormal bowel motility issues. Patients with any
of these conditions were excluded from the clinical trials and
the safety of the use of patiromer in these patients is unknown. Hypomagnesemia is a concern because patiromer
binds to magnesium in the colon. Serum magnesium needs to
be monitored and supplementation considered, if necessary.
In one trial designed to examine the safety and efficacy of
patiromer for the treatment of hyperkalemia (OPAL-HK),
patiromer was examined for its potassium lowering effect in
patients with mild to moderate hyperkalemia (serum levels
5.1 to 6.5 mmol per liter), with stage 3 or 4 chronic kidney
disease, with or without diabetes or heart failure and receiving a stable dose of one or more RAS inhibitors for greater
than 28 days.43 The trial was conducted in two phases; a four
week open-label initial treatment phase, followed by an eight
week withdrawal phase where eligible patients from the initial phase were randomized to continue on patiromer or
switch to placebo. Of the 237 patients in the initial phase, 76
percent achieved the target potassium level (3.8 to 5.1
mmol/L) and 107 patients were entered into the second
randomized controlled phase. At the end of eight weeks a

significant reduction in recurrence of hyperkalemia was
demonstrated with patiromer as compared to placebo.
Eleven percent of the patients experienced mild to moderate
constipation on patiromer and 3 percent experienced hypokalemia.
A subgroup analysis of the OPAL-HK trial published by Pitt et
al. found significantly improved potassium levels in heart
failure patients treated with patiromer as compared to heart
failure patients treated with placebo.44 An earlier multicenter, randomized, double-blind trial conducted by Pitt et al.,
also looked at the use of patiromer in heart failure patients
(PEARL-HF).45 Patients were included if they had a history of
chronic heart failure with an indication for spironolactone, a
serum potassium of 4.3 to 5.1 mEq/L and either chronic kidney disease (defined as estimated glomerular filtration rate
less than 60 mL/min) or previous history of hyperkalemia
such that an RAS inhibitor was discontinued or dosing
suboptimized. The investigators found a significant decrease
in potassium in patients receiving patiromer as compared to
placebo after four weeks.
A study by Bakris et al. examined the use of patiromer in the
treatment of hyperkalemia in patients with hypertension and
diabetic nephropathy (AMETHYST-DN).46 Although this was
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an open-label, dose-finding study, 77 to 95 percent of participants maintained normokalemia over a 52 week period. and
RAS inhibitor therapy was maintained in 94 percent of patiromer-treated patients after 12 weeks.
Sodium zirconium (ZS-9) is insoluble and remains in the intestine working to selectively trap potassium and ammonium
in the gastrointestinal (GI) tract.1 In the Hyperkalemia Randomized Intervention Multidose ZS-9 Maintenance
(HARMONIZE) trial, ambulatory patients with a potassium
level greater than 5.1 mEq/L were given an open-label trial
of ZS-9 for 48 hours to determine response.47 The responders were then blindly randomized to three different dosing
regimens or placebo for a 28 day trial. In the initial openlabel phase, median time to normalization of the potassium
level was 2.2 hours with 98 percent of patients achieving
normokalemia by 48 hours. Serum potassium was significantly lowered in all three dosing groups of ZS-9 as compared to placebo. Adverse events were comparable between
ZS-9 treated patients and the placebo group with the exception of edema more common in the 15 gram ZS-9 group
(14 percent versus 6 percent, 2 percent and 2 percent in the
10 gram, 5 gram and placebo groups) and hypokalemia occurred in both the 10 gram (10 percent) and 15 gram
(11 percent) group as compared to no patients in the 5 gram
or placebo groups. Based on the results of this trial, sodium
zirconium may represent an acute and short-term treatment
method for hyperkalemia, but further data is needed to support safety and efficacy over the long term. Sodium zirconium was expected to receive approval for use in the United
States, but the FDA has cited issues with the pre-approval
manufacturing inspections for the second time and has not
yet given approval.48
In 2004 Palmer reviewed the need for balancing the benefits
of medications such as RAS inhibitors and potassium-sparing
diuretics with the risk of inducing hyperkalemia particularly
in the chronic heart failure patient and patients with diabetic
nephropathy.3 The author discussed the need to decrease
doses or discontinue these potentially life-saving drugs in
order to avoid the potential for hyperkalemia. At the time of
this review, sodium-polystyrene-sulfonate was determined
to be poorly tolerated long term and was associated with
intestinal mucosal injury.49,50 The use of acute management
techniques such as insulin/glucose or beta-agonists is considered impractical for the outpatient setting. 3 The information from the clinical trials with both patiromer and sodium zirconium provides support for a method to control potassium levels, but still allow patients to continue on the best
regimen (RAS inhibitors and potassium-sparing diuretics)
for heart failure management and hypertension in the face of
diabetic nephropathy. In regard to adverse effects, both
drugs seem to be well-tolerated with the most common
events reported pertaining to the GI tract (constipation, nausea and diarrhea).42-47 Multiple studies did note reported
cases of hypomagnesemia with both medications.45-47 Most
information regarding both sodium zirconium and patiromer
is based upon 12 weeks of treatment.42-47 Long-term studies
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are needed to further explore the place in therapy for these
drugs.
Conclusion
Hyperkalemia, if not treated immediately, can result in cardiac arrhythmias that may be fatal. Hyperkalemia is often difficult to diagnose due to vague symptomatology and lack of
consistency in the correlation between abnormal ECG
findings and lab values. Inpatient strategies to manage
hyperkalemia are largely dependent on the severity of hyperkalemia. Agents used to treat hyperkalemia include cation
exchange resins, loop diuretics, insulin, sodium bicarbonate,
beta-agonists and calcium infusions. Nurses and pharmacists
both have significant roles to ensure timely, comprehensive
treatment for the patients. In outpatient and ambulatory settings, it is important to screen for any medications that have
the potential to cause hyperkalemia and provide patient education to decrease the patient’s risk for developing a hyperkalemic emergency. Long-term, outpatient management of
chronic hyperkalemia is limited, but emerging therapies are
being evaluated in clinical trials. These therapies include
sodium zirconium and patiromer. Prevention and timely
recognition and treatment of hyperkalemic emergencies are
imperative in preventing cardiac arrest in patients.
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